132 related articles for article (PubMed ID: 17965607)
1. The epigenetic modifier, valproic acid, enhances radiation sensitivity.
Karagiannis TC; Kn H; El-Osta A
Epigenetics; 2006; 1(3):131-7. PubMed ID: 17965607
[TBL] [Abstract][Full Text] [Related]
2. Effect of valproic acid on radiation-induced DNA damage in euchromatic and heterochromatic compartments.
Harikrishnan KN; Karagiannis TC; Chow MZ; El-Osta A
Cell Cycle; 2008 Feb; 7(4):468-76. PubMed ID: 18239454
[TBL] [Abstract][Full Text] [Related]
3. Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma.
Shoji M; Ninomiya I; Makino I; Kinoshita J; Nakamura K; Oyama K; Nakagawara H; Fujita H; Tajima H; Takamura H; Kitagawa H; Fushida S; Harada S; Fujimura T; Ohta T
Int J Oncol; 2012 Jun; 40(6):2140-6. PubMed ID: 22469995
[TBL] [Abstract][Full Text] [Related]
4. The histone deacetylase inhibitor, Trichostatin A, enhances radiation sensitivity and accumulation of gammaH2A.X.
Karagiannis TC; Harikrishnan KN; El-Osta A
Cancer Biol Ther; 2005 Jul; 4(7):787-93. PubMed ID: 16082178
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid.
Camphausen K; Cerna D; Scott T; Sproull M; Burgan WE; Cerra MA; Fine H; Tofilon PJ
Int J Cancer; 2005 Apr; 114(3):380-6. PubMed ID: 15578701
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01.
Yeow WS; Ziauddin MF; Maxhimer JB; Shamimi-Noori S; Baras A; Chua A; Schrump DS; Nguyen DM
Br J Cancer; 2006 May; 94(10):1436-45. PubMed ID: 16705314
[TBL] [Abstract][Full Text] [Related]
7. The paradox of histone deacetylase inhibitor-mediated modulation of cellular responses to radiation.
Karagiannis TC; El-Osta A
Cell Cycle; 2006 Feb; 5(3):288-95. PubMed ID: 16418577
[TBL] [Abstract][Full Text] [Related]
8. Clinical potential of histone deacetylase inhibitors as stand alone therapeutics and in combination with other chemotherapeutics or radiotherapy for cancer.
Karagiannis TC; El-Osta A
Epigenetics; 2006; 1(3):121-6. PubMed ID: 17965606
[TBL] [Abstract][Full Text] [Related]
9. Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells.
Thotala D; Karvas RM; Engelbach JA; Garbow JR; Hallahan AN; DeWees TA; Laszlo A; Hallahan DE
Oncotarget; 2015 Oct; 6(33):35004-22. PubMed ID: 26413814
[TBL] [Abstract][Full Text] [Related]
10. Radiosensitivity enhancement of human thyroid carcinoma cells by the inhibitors of histone deacetylase sodium butyrate and valproic acid.
Perona M; Thomasz L; Rossich L; Rodriguez C; Pisarev MA; Rosemblit C; Cremaschi GA; Dagrosa MA; Juvenal GJ
Mol Cell Endocrinol; 2018 Dec; 478():141-150. PubMed ID: 30125607
[TBL] [Abstract][Full Text] [Related]
11. HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells.
Chen X; Wong P; Radany E; Wong JY
Cancer Biother Radiopharm; 2009 Dec; 24(6):689-99. PubMed ID: 20025549
[TBL] [Abstract][Full Text] [Related]
12. Modulation of radiation response by histone deacetylase inhibition.
Chinnaiyan P; Vallabhaneni G; Armstrong E; Huang SM; Harari PM
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):223-9. PubMed ID: 15850925
[TBL] [Abstract][Full Text] [Related]
13. The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver.
Eyal S; Lamb JG; Smith-Yockman M; Yagen B; Fibach E; Altschuler Y; White HS; Bialer M
Br J Pharmacol; 2006 Oct; 149(3):250-60. PubMed ID: 16894351
[TBL] [Abstract][Full Text] [Related]
14. Postradiation sensitization of the histone deacetylase inhibitor valproic acid.
Chinnaiyan P; Cerna D; Burgan WE; Beam K; Williams ES; Camphausen K; Tofilon PJ
Clin Cancer Res; 2008 Sep; 14(17):5410-5. PubMed ID: 18765532
[TBL] [Abstract][Full Text] [Related]
15. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells.
Catalano MG; Fortunati N; Pugliese M; Poli R; Bosco O; Mastrocola R; Aragno M; Boccuzzi G
J Endocrinol; 2006 Nov; 191(2):465-72. PubMed ID: 17088416
[TBL] [Abstract][Full Text] [Related]
16. Induction of GRP78 by valproic acid is dependent upon histone deacetylase inhibition.
Shi Y; Gerritsma D; Bowes AJ; Capretta A; Werstuck GH
Bioorg Med Chem Lett; 2007 Aug; 17(16):4491-4. PubMed ID: 17566732
[TBL] [Abstract][Full Text] [Related]
17. Radiosensitization of cervical cancer cells with epigenetic drugs hydralazine and valproate.
Mani E; Medina LA; Isaac-Olivé K; Dueñas-González A
Eur J Gynaecol Oncol; 2014; 35(2):140-2. PubMed ID: 24772915
[TBL] [Abstract][Full Text] [Related]
18. Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation.
Ziauddin MF; Yeow WS; Maxhimer JB; Baras A; Chua A; Reddy RM; Tsai W; Cole GW; Schrump DS; Nguyen DM
Neoplasia; 2006 Jun; 8(6):446-57. PubMed ID: 16820090
[TBL] [Abstract][Full Text] [Related]
19. Novel HDAC inhibitors with radiosensitizing properties.
Jung M; Velena A; Chen B; Petukhov PA; Kozikowski AP; Dritschilo A
Radiat Res; 2005 May; 163(5):488-93. PubMed ID: 15850409
[TBL] [Abstract][Full Text] [Related]
20. Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation.
Lopez CA; Feng FY; Herman JM; Nyati MK; Lawrence TS; Ljungman M
Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):214-20. PubMed ID: 17707275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
